[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial):a single-centre, single-arm, phase 2 study - Hofman, MS; Violet, J; Hicks, RJ (Lancet Oncol, 2018)
et al.